Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?
暂无分享,去创建一个
[1] A. Shandilya,et al. Sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2023, Disease-a-month : DM.
[2] Stefan L. Zimmerman,et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy , 2022, European heart journal.
[3] T. B. Rasmussen,et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2021, Journal of the American College of Cardiology.
[4] W. Zareba,et al. Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome. , 2021, Journal of the American College of Cardiology.
[5] P. Postema,et al. Brugada syndrome: update and future perspectives , 2021, Heart.
[6] P. Schwartz,et al. Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management. , 2021, JACC. Clinical electrophysiology.
[7] Derick R. Peterson,et al. Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[8] P. Schwartz,et al. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. , 2021, European heart journal.
[9] E. Ashley,et al. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. , 2021, European heart journal.
[10] H. Calkins,et al. Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[11] J. Roos‐Hesselink,et al. Implantable loop recorders in patients with heart disease: comparison between patients with and without syncope , 2021, Open Heart.
[12] J. Triedman,et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. , 2021, Heart rhythm.
[13] D. Corrado,et al. Arrhythmic risk stratification in arrhythmogenic cardiomyopathy: new predictors for left-sided variants? , 2021, European heart journal.
[14] A. Zwinderman,et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction , 2021, European heart journal.
[15] P. Schwartz,et al. Precision Medicine and cardiac channelopathies: when dreams meet reality , 2021, European heart journal.
[16] P. Delise. Risk stratification in Brugada syndrome: the challenge of the grey zone. , 2021, European heart journal.
[17] Stefan L. Zimmerman,et al. Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy , 2020, Circulation. Arrhythmia and electrophysiology.
[18] F. Sacher,et al. Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome. , 2020, European heart journal.
[19] M. Ackerman,et al. Left Cardiac Sympathetic Denervation Monotherapy in Patients With Congenital Long QT Syndrome , 2020, Circulation. Arrhythmia and electrophysiology.
[20] P. Schwartz. 1970-2020: 50 years of research on the long QT syndrome-from almost zero knowledge to precision medicine. , 2020, European heart journal.
[21] G. T. Gunnarsson,et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. , 2020, European heart journal.
[22] P. Lambiase,et al. Subcutaneous or Transvenous Defibrillator Therapy , 2020, New England Journal of Medicine.
[23] M. Link,et al. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. , 2020, The American journal of cardiology.
[24] P. Schwartz,et al. Inherited cardiac arrhythmias , 2020, Nature Reviews Disease Primers.
[25] B. Maron,et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. , 2020, Journal of the American College of Cardiology.
[26] S. Colan,et al. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.
[27] P. Sham,et al. MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes , 2020, Cardiovascular research.
[28] N. Sreeram,et al. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. , 2019, Heart rhythm.
[29] J. Skinner,et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. , 2019, European heart journal.
[30] B. Wessler,et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. , 2019, Circulation. Cardiovascular interventions.
[31] K. Mandal,et al. Cardiac sympathectomy for refractory ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy. , 2019, Heart Rhythm.
[32] M. Link,et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.
[33] E. Behr,et al. Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. , 2019, European heart journal.
[34] P. Schwartz,et al. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. , 2019, Circulation. Arrhythmia and electrophysiology.
[35] P. Schwartz,et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. , 2018, Heart rhythm.
[36] D. Corrado,et al. Sport activity in patients with implantable defibrillator: Playing with death? , 2018, European journal of preventive cardiology.
[37] E. Ashley,et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.
[38] J. Healey,et al. An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis , 2018, European heart journal.
[39] P. Schwartz,et al. Modifier genes for sudden cardiac death , 2018, European heart journal.
[40] A. Abidov,et al. Arrhythmogenic cardiomyopathy , 2018, The EACVI Textbook of Cardiovascular Magnetic Resonance.
[41] B. Maron,et al. Clinical Course and Management of Hypertrophic Cardiomyopathy , 2018, The New England journal of medicine.
[42] R. Bellazzi,et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. , 2018, Journal of the American College of Cardiology.
[43] S. Viskin. Radiofrequency Ablation of Asymptomatic Brugada Syndrome: Don't Go Burning My Heart. , 2018, Circulation.
[44] H. Calkins,et al. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2018, Circulation: Arrhythmia and Electrophysiology.
[45] D. Lacroix,et al. Catheter ablation reduces ventricular tachycardia burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from a north-western French multicentre registry , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[46] Jian Zhang,et al. Long-Term Prognosis after Myectomy in Hypertrophic Obstructive Cardiomyopathy with Severe Left Ventricular Hypertrophy , 2018, Cardiology.
[47] L. Eckardt,et al. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults. , 2017, JACC. Clinical electrophysiology.
[48] A. Keren,et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.
[49] H. Calkins,et al. Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy , 2017, Circulation.
[50] D. Judge,et al. Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis , 2017, Cardiovascular research.
[51] E. Braunwald,et al. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.
[52] Marmar Vaseghi,et al. Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. , 2017, Journal of the American College of Cardiology.
[53] P. Brugada,et al. A score model to predict risk of events in patients with Brugada Syndrome , 2017, European heart journal.
[54] Toshihiro Tanaka,et al. Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry , 2017, Circulation.
[55] A. von Eckardstein,et al. Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome , 2017, European heart journal.
[56] J. Brugada,et al. Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome , 2017, Circulation. Arrhythmia and electrophysiology.
[57] M. Link,et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.
[58] G. Hindricks,et al. Should all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergo epicardial catheter ablation? , 2017, Journal of Interventional Cardiac Electrophysiology.
[59] M. Link,et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. , 2017, Journal of the American College of Cardiology.
[60] M. Link,et al. Arrhythmogenic Right Ventricular Cardiomyopathy. , 2017, The New England journal of medicine.
[61] A. Wilde,et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. , 2016, Journal of the American College of Cardiology.
[62] B. Belhassen. Management of Brugada Syndrome 2016: Should All High Risk Patients Receive an ICD? Alternatives to Implantable Cardiac Defibrillator Therapy for Brugada Syndrome. , 2016, Circulation. Arrhythmia and electrophysiology.
[63] H. Huikuri,et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge , 2016, Journal of arrhythmia.
[64] S. Khalsa,et al. Clinical neurocardiology defining the value of neuroscience‐based cardiovascular therapeutics , 2016, The Journal of physiology.
[65] D. Corrado,et al. Implantable cardioverter defibrillator therapy in young patients with cardiomyopathies and channelopathies: a single Italian centre experience , 2016, Journal of cardiovascular medicine.
[66] K. Shivkumar,et al. Role of Bilateral Sympathectomy in the Treatment of Refractory Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. , 2016, Circulation. Arrhythmia and electrophysiology.
[67] D. Corrado,et al. Relationship Between Arrhythmogenic Right Ventricular Cardiomyopathy and Brugada Syndrome: New Insights From Molecular Biology and Clinical Implications , 2016, Circulation. Arrhythmia and electrophysiology.
[68] D. Lin,et al. Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy , 2015, Circulation. Arrhythmia and electrophysiology.
[69] P. Ellinor,et al. Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis , 2016, Circulation.
[70] Pier D. Lambiase,et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[71] M. Link,et al. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2015, Circulation.
[72] P. Brugada,et al. Prognostic Value of Programmed Electrical Stimulation in Brugada Syndrome: 20 Years Experience , 2015, Circulation. Arrhythmia and electrophysiology.
[73] M. Link,et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement , 2015, European heart journal.
[74] P. Schwartz,et al. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. , 2015, Circulation.
[75] P. Brugada,et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. , 2015, Journal of the American College of Cardiology.
[76] T. Edvardsen,et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members , 2014, European journal of heart failure.
[77] P. Schwartz,et al. AKAP9 Is a Genetic Modifier of Congenital Long-QT Syndrome Type 1 , 2014, Circulation. Cardiovascular genetics.
[78] Giuseppe Limongelli,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.
[79] M. Link,et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. , 2014, Journal of the American College of Cardiology.
[80] D. Pennell,et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy , 2014, Heart.
[81] P. Schwartz. Cardiac sympathetic denervation to prevent life-threatening arrhythmias , 2014, Nature Reviews Cardiology.
[82] S. Priori,et al. Novel Insight Into the Natural History of Short QT Syndrome , 2014, Journal of the American College of Cardiology.
[83] L. Held,et al. Different Prognostic Value of Functional Right Ventricular Parameters in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2014, Circulation. Cardiovascular imaging.
[84] D. Corrado,et al. Compound and Digenic Heterozygosity Predicts Lifetime Arrhythmic Outcome and Sudden Cardiac Death in Desmosomal Gene–Related Arrhythmogenic Right Ventricular Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.
[85] C. Tracy,et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.
[86] Michael J Ackerman,et al. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. , 2013, European heart journal.
[87] S. Russell,et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. , 2013, Journal of the American College of Cardiology.
[88] L. Jordaens,et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. , 2013, American heart journal.
[89] P. Schwartz,et al. Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier Against Arrhythmic Risk in Long-QT Syndrome , 2013, Circulation. Cardiovascular genetics.
[90] M. Link,et al. Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry , 2013, Circulation.
[91] A. Bassett,et al. The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43 , 2013, Clinical genetics.
[92] Wataru Shimizu,et al. Long-term follow-up of a pediatric cohort with short QT syndrome. , 2013, Journal of the American College of Cardiology.
[93] Thomas Meitinger,et al. Calmodulin Mutations Associated With Recurrent Cardiac Arrest in Infants , 2013, Circulation.
[94] C. Poggesi,et al. Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy , 2013, Circulation.
[95] Arthur A M Wilde,et al. The ICD for Primary Prevention in Patients With Inherited Cardiac Diseases: Indications, Use, and Outcome: A Comparison With Secondary Prevention , 2013, Circulation. Arrhythmia and electrophysiology.
[96] D. Corrado,et al. Prognostic Value of Endocardial Voltage Mapping in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2013, Circulation. Arrhythmia and electrophysiology.
[97] S. Russell,et al. Risk Stratification in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy–Associated Desmosomal Mutation Carriers , 2012, Circulation. Arrhythmia and electrophysiology.
[98] R. Hauer,et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. , 2012, Journal of the American College of Cardiology.
[99] A. Leenhardt,et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[100] M. Ackerman,et al. Videoscopic Left Cardiac Sympathetic Denervation for Patients With Recurrent Ventricular Fibrillation/Malignant Ventricular Arrhythmia Syndromes Besides Congenital Long-QT Syndrome , 2012, Circulation. Arrhythmia and electrophysiology.
[101] S. Priori,et al. [Risk stratification in Brugada syndrome]. , 2011, Giornale italiano di cardiologia.
[102] S. Russell,et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. , 2011, Journal of the American College of Cardiology.
[103] Andrea Mazzanti,et al. Long-term follow-up of patients with short QT syndrome. , 2011, Journal of the American College of Cardiology.
[104] A. Wilde,et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. , 2011, Journal of the American College of Cardiology.
[105] L. Mestroni,et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. , 2011, European heart journal.
[106] Tachapong Ngarmukos,et al. Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract Epicardium , 2011, Circulation.
[107] B. Gersh,et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.
[108] L. Jordaens,et al. Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?: Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry , 2010, Circulation.
[109] M. Link,et al. Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia , 2010, Circulation.
[110] P. Schwartz. Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: medicolegal complications. , 2010, Heart rhythm.
[111] P. Schwartz,et al. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. , 2010, Heart rhythm.
[112] M Borggrefe,et al. Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry , 2010, Circulation.
[113] P. Schwartz,et al. NOS1AP Is a Genetic Modifier of the Long-QT Syndrome , 2009, Circulation.
[114] E. Kaufman,et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. , 2009, Journal of the American College of Cardiology.
[115] G. Marcus,et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. , 2009, Journal of the American College of Cardiology.
[116] P. Schwartz. Cutting nerves and saving lives. , 2009, Heart rhythm.
[117] M. Ackerman,et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. , 2009, Heart rhythm.
[118] A. Leenhardt,et al. Incidence and Risk Factors of Arrhythmic Events in Catecholaminergic Polymorphic Ventricular Tachycardia , 2009, Circulation.
[119] C. Autore,et al. Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.
[120] M. Gollob,et al. Sudden Death in a Young Man with Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation , 2008, Journal of cardiovascular electrophysiology.
[121] P. Schwartz,et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. , 2008, The New England journal of medicine.
[122] A. Tajik,et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.
[123] M. Link,et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.
[124] Andrew J. Sauer,et al. Long QT syndrome in adults. , 2007, Journal of the American College of Cardiology.
[125] A. Krahn,et al. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. , 2006, Heart rhythm.
[126] W. Manning,et al. Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.
[127] Lauri Toivonen,et al. The Jervell and Lange-Nielsen Syndrome: Natural History, Molecular Basis, and Clinical Outcome , 2006, Archives des maladies du coeur et des vaisseaux.
[128] Dan M Roden,et al. KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome , 2005, Circulation.
[129] C. Autore,et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. , 2005, Journal of the American College of Cardiology.
[130] Arthur J Moss,et al. 25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome. , 2005, Circulation.
[131] X. Jouven,et al. Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2004, Circulation.
[132] S. Priori,et al. CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism , 2004, Cell.
[133] S. Viskin,et al. Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome , 2004, Circulation.
[134] S. Priori,et al. Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.
[135] M. Sanguinetti,et al. Compound Mutations: A Common Cause of Severe Long-QT Syndrome , 2004, Circulation.
[136] G. Breithardt,et al. Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients , 2004, Circulation.
[137] M. Link,et al. Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.
[138] J. Brugada,et al. Determinants of Sudden Cardiac Death in Individuals With the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest , 2003, Circulation.
[139] Carlo Napolitano,et al. How Really Rare Are Rare Diseases?: , 2003, Journal of cardiovascular electrophysiology.
[140] P. Elliott,et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.
[141] Carlo Napolitano,et al. Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.
[142] Derick R. Peterson,et al. Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel , 2002, Circulation.
[143] G. Breithardt,et al. Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .
[144] G Thiene,et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.
[145] B. Maron,et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[146] M. Link,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[147] S. Priori,et al. Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. , 1998, The New England journal of medicine.
[148] S. Priori,et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.
[149] A. Moss,et al. The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.
[150] A. Moss,et al. Left Cardiac Sympathetic Denervation in the Therapy of Congenital Long QT Syndrome: A Worldwide Report , 1991, Circulation.
[151] D. Corrado,et al. Right ventricular cardiomyopathy and sudden death in young people. , 1988, The New England journal of medicine.
[152] P. Schwartz. The idiopathic long QT syndrome: the need for a prospective registry. , 1983, European heart journal.
[153] H. L. Stone,et al. Left stellectomy and denervation supersensitivity in conscious dogs. , 1982, The American journal of cardiology.
[154] H. L. Stone,et al. Effects of Unilateral Stellectomy upon Cardiac Performance during Exercise in Dogs , 1979, Circulation research.
[155] H. L. Stone,et al. Tonic influence of the sympathetic nervous system on myocardial reactive hyperemia and on coronary blood flow distribution in dogs. , 1977, Circulation research.
[156] P. Schwartz,et al. Effect of Stellectomy and Vagotomy on Ventricular Refractoriness in Dogs , 1977, Circulation research.
[157] A. Malliani,et al. The long Q-T syndrome. , 1975, American heart journal.
[158] A. Moss,et al. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. , 1971, The New England journal of medicine.
[159] OUP accepted manuscript , 2022, European Heart Journal.
[160] P. Schwartz,et al. Long and Short QT Syndromes , 2018 .
[161] William J. Bryant,et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.
[162] P. Schwartz. When the risk is sudden death, does quality of life matter? , 2016, Heart rhythm.
[163] M. Ackerman,et al. Quality of life after videoscopic left cardiac sympathetic denervation in patients with potentially life-threatening cardiac channelopathies/cardiomyopathies. , 2016, Heart rhythm.
[164] H. Huikuri,et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. , 2016, Heart rhythm.
[165] KoonlaweeNademanee,et al. Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract Epicardium , 2011 .
[166] J. Graham. Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy , 2010 .
[167] P. Schwartz,et al. All LQT3 patients need an ICD: true or false? , 2009, Heart rhythm.
[168] M. Bitner-Glindzicz,et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. , 2006, Circulation.
[169] A. Moss,et al. The long QT syndrome: a prospective international study. , 1985, Circulation.
[170] P. Schwartz,et al. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. , 1976, The American journal of cardiology.
[171] A Malliani,et al. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. , 1975, American heart journal.